GLP1R and type 2 diabetes mellitus: A meta-analysis (seven studies, n=56004) of the Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) and Peptide Innovation for Early Diabetes Treatment (PIONEER 6) trials reported that GLP-1 receptor agonists reduced all-cause mortality by 11% and microalbuminuria (HR: 0.76 (0.68-0.86), p=0.003) when compared to placebo in individuals with T2D [98].